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Pain management is the pillar of caring for patients with traumatic rib fractures. Intravenous
lidocaine (IVL) is a well-established non-opioid analgesic for post-operative pain, yet its effi-
cacy has yet to be investigated in trauma patients. We hypothesized that IVL is associated
with decreased inpatient opioid requirements among patients with rib fractures.
Methods
We retrospectively evaluated adult patients presenting to our Level 1 trauma center with iso-
lated chest wall injuries. After 1:1 propensity score matching patients who received vs did
not receive IVL, we compared the two groups’ average daily opioid use, opioid use in the
last 24 hours of admission, and pain scores during admissions hours 24–48. We performed
multivariable linear regression for these outcomes (with sensitivity analysis for the opioid
use outcomes), adjusting for age as a moderating factor and controlling for hospital length of
stay and injury severity.
Results
We identified 534 patients, among whom 226 received IVL. Those who received IVL were
older and had more serious injury. Compared to propensity-score matched patients who did
not receive IVL, patients who received IVL had similar average daily opioid use and pain
scores, but 40% lower opioid use during the last 24 hours of admission (p = 0.002). Multivari-
able regression–with and without sensitivity analysis–did not show an effect of IVL on any
outcomes.
Conclusion
IVL was crudely associated with decreased opioid requirements in the last 24 hours of
admission, the time period associated with opioid use at 90 days post-discharge. However,
we did not observe beneficial effects of IVL on multivariable adjusted analyses; we are
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conducting a randomized control trial to further evaluate IVL’s opioid-sparing effects for
patients with rib fractures.
Introduction
Traumatic rib fractures confer significant morbidity and mortality. Poor respiratory effort lim-
ited by pain can result in pneumonia, respiratory failure, and ultimately, death [1–3]. This
injury pattern is a growing problem: between 2006 and 2014, the incidence of rib fractures
increased 19.4% despite a 12.9% decrease in emergency department visits for traumatic injury
[4]. Rib fracture patients frequently require opioids for adequate pain management. However,
known side effects of respiratory depression, the national spotlight on curbing opioid utiliza-
tion, and risk of chronic opioid dependence after inpatient utilization have motivated physi-
cians to investigate non-opioid adjunct analgesics [5–10]. Receipt of opioids during the last 24
hours of hospitalization may be an especially important measure, as this has been shown to be
associated with opioid use at 90 days post-discharge [11]. Limiting opioid utilization is particu-
larly critical for elderly patients (age�65 years) who are more vulnerable to side effects and
are at higher risk of complications associated with rib fractures [12–14].
The efficacy of intravenous lidocaine (IVL) as an adjunct analgesic in rib fractures has not
been investigated. Lidocaine is a widely used analgesic that is short-acting, easy to titrate, and
has anti-inflammatory properties along with one of the best anesthetic safety profiles [15–17].
Even one dose of IVL has long-lasting analgesic effects, purportedly due to a continuous active
biological response to lidocaine. Systemic IVL has been widely studied in surgical literature.
Multiple meta-analyses have shown its efficacy in lowering opioid requirements, reducing
pain scores, and decreasing hospital length of stay after abdominal operations [18–21]. Similar
efficacy has been demonstrated in randomized controlled trials and meta-analyses of utiliza-
tion in thoracic and breast operations [22–25].
Starting in 2012, our institution implemented an option for physicians to order systemic
IVL as a non-opioid adjunct analgesic for patients with rib fractures. We aimed to assess
whether this new pain management approach was associated with decreased opioid usage. We
hypothesized that patients who received IVL would have lower hospital opioid utilization and
similar pain scores as matched patients who did not receive IVL.
Methods
Study population
Using our institution’s trauma registry and electronic medical records (EMR) from 2012–
2017, we retrospectively evaluated adult patients (age�18) admitted to our Level I trauma cen-
ter with isolated chest wall injuries (Abbreviated Injury Scale, AIS chest�3 and all other AIS
other body regions <3). Of note, injury severity of trauma patients is quantified using the
Injury Severity Score (ISS): ISS = A2+B2+C2, where A, B, and C, are AIS of the three most
severely injured body regions. AIS for the six body regions range from 1 (minor) to 6 (unsurvi-
vable). Stanford’s Institutional Review Board approved this study and waived informed con-
sent requirement for this retrospective EMR study.
Exclusion criteria
Patients were excluded if they had 1) chronic opioid dependence (defined by diagnosis on the
patient problem list), 2) rib fractures due to cardiopulmonary resuscitation, 3) presentation to
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the hospital greater than 24 hours after injury, or 4) discharge from the emergency department
without inpatient admission as determined by EMR review.
Lidocaine protocol
IVL infusion was started at 1mg/kg/hr. Systemic lidocaine levels were measured every 8 hours
(therapeutic range 1.5–5 mcg/mL). While bolus dose of 1–1.5 mg/kg is standard practice for
perioperative IVL, bolus dose was removed from rib fracture IVL protocol in favor of longer
time to therapeutic level (several hours) and mitigating side effects. IVL infusion rate was
titrated either by the surgical intensive care unit (SICU) or pain management service (for
patients not in the SICU) for adequate analgesia (NRS�4) within therapeutic plasma levels.
Trained nursing staff and SICU or pain management service monitored potential side effects,
which include but are not limited to bradycardia, arrhythmia, numbness, metallic taste, dizzi-
ness, or headaches. All patients on IVL had visible bedside sign indicating they were on IVL
infusion.
Measures
Exposure variable. IVL infusion (yes/no) was the main explanatory variable. Patients
were assigned to the IVL group if they received any lidocaine over the course of their stay.
Outcomes variables. The outcomes of interests were: mean daily opioids administered
during the hospitalization, total opioids administered in the last 24 hours of hospitalization,
and mean 0–10 numeric rating scale (NRS) pain score measured from 24–48 hours after
admission. Opioid administration data (via oral, intravenous, patient controlled analgesia
(PCA), or patch) was aggregated from EMR and converted to total oral morphine equivalents
(OME) using established conversion factors [26]. We excluded palliative morphine infusion
for dyspnea and neuraxial opioids (high variability in systemic permeability and OME conver-
sion factors) [27]. Daily opioid administration was calculated as the total OME over the hospi-
talization period divided by the total number of days hospitalized. Opioids administered in the
last 24 hours of hospitalization was the total sum of OMEs in the that time. The mean NRS
pain score was calculated as the average pain score of all measurements taken within a range of
24–48 hours from admission.
Additional clinical information. Additional information captured from the EMR and
trauma registry included patient age, gender, smoking status, ISS, mechanism of injury, num-
ber of rib fractures, presence of pulmonary contusion, and presence of scapular, clavicular or
sternal fractures. We assessed hospitalization characteristics including hospital length of stay
(LOS), SICU admission, incidence of pneumonia, discharge disposition, 30-day readmission
rates, and mortality during hospitalization.
Data analysis
Descriptive statistics were calculated within study groups, including frequencies, proportions,
medians and interquartile ranges. We assessed the trend of IVL use within the study popula-
tion over time in one-year intervals using the Mann-Kendall test (“Kendall” package in R)
[28].
Propensity score models
To account for the potential treatment selection bias in administration of IVL, we performed
propensity score (PS) matching between patients who received IVL and those who did not.
We applied a 1:1 optimal matching model without replacement, matching for age, number of
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rib fractures, initial pain score (mean NRS pain score during the first 6 hours of admission),
presence of pulmonary contusion, and presence of scapular, clavicular or sternal fractures.
Matching was performed using the “Matchit” package in R [29].
Statistical analysis
Data analysis was conducted using the PS-matched data. Categorical variables were analyzed
using chi-square tests (if expected cell sizes� 5) or Fisher’s exact tests (if any expected cell
size < 5), and continuous variables were analyzed using Mann-Whitney U tests due to non-
parametric distributions of OME measures and pain scores. Simple and multivariable linear
regression models were calculated using the “lm()” function from the “stats” R package (three
study outcomes: mean daily OME, total last 24 hours OME, and mean NRS) [30]. Primary pre-
dictive variables in the models included receipt of IVL, age category (<65 vs.�65 years), and
the interaction effect of age on receipt of IVL (age category x IVL), while adjusting for ISS and
hospital LOS as covariates. As the OME outcome measures demonstrated moderate skewness
and kurtosis, we performed sensitivity analyses to recalculate linear regression models after
applying square-root transformations of mean daily OME and total OME in the last 24 hours.




During the 6-year study period, we identified 534 adult patients with isolated chest wall
injuries in our trauma registry. Among those, 42.3% (n = 226) received IVL. Demographic,
injury, and hospitalization characteristics are presented in Table 1. The IVL group was
older than the non-IVL group (median age: 67.5 vs 54.5 years, p<0.001). IVL administra-
tion was initiated a mean (±SD) of 11.3 (±21.6) hours after admission and infused for a
mean (±SD) duration of 55.9 hours (±53.6). The proportion of patients receiving IVL
increased throughout our study period from 9.1% in 2012 to 63.6% in 2017 (p = 0.002) (Fig
1). Compared to the non-IVL group, patients who received IVL had more serious injuries
(ISS > 15: IVL 32.3% vs non-IVL 20.8%, p = 0.006) and greater number of rib fractures
(median: IVL 6 vs non-IVL 5, p<0.001). The rates of pulmonary contusion (36.3% vs
39.3%, p = 0.54) and other fractures (sternal: 8.0% vs 9.4%, p = 0.667; clavicular: 13.7% vs
14.9%, p = 0.79; scapular: 11.1% vs 13.3%, p = 0.52) were not significantly different between
IVL and non-IVL groups. The most common mechanisms of injury were ground level fall
(25.7%) and motor vehicle collision (24.8%) for the IVL group, and motor vehicle collision
(26.6%) and bicycle accident (21.4%) for the non-IVL group. Compared to the non-IVL
group, the IVL group had longer hospital LOS (median LOS: 5 vs 3 days, p<0.001), were
more likely to be admitted to ICU (76.1% vs 34.7%, p<0.001), and more likely to be dis-
charged to a skilled nursing facility (25.2% vs 9.7%, discharge disposition p<0.001). 30-day
readmission rates were similar between the IVL and non-IVL groups (2.2% vs 1.3%,
p = 0.50), but the IVL group had higher rates of pneumonia (6.6% vs 0.3%, p<0.001) and
mortality (3.1% vs 0.6%, p = 0.04). No patient in the IVL group had supratherapeutic lido-
caine plasma levels or hemodynamically significant side effects.
Propensity score matching analysis
After propensity score matching, all 226 patients in the IVL group were matched with 226 of
the non-IVL group (73.3% of 304 total non-IVL group). Overall, the matching improved
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Table 1. Demographic, injury, and hospitalization characteristics of adult isolated chest wall injury patients on vs not on IVL infusion.
IVL No IVL
Median (IQR) or Number (%) Median (IQR) or Number (%) p
n = 226 n = 308
Demographic characteristics
Age 67.5 (56.3–81.0) 54.5 (41.8–65.0) <0.001
Gender 0.009
Male 141 (62.4%) 226 (73.4%)
Female 85 (37.6%) 82 (26.6%)
Smoking status <0.001
Active 28 (12.4%) 58 (18.8%)
Former 47 (20.8%) 42 (13.6%)
Never 143 (63.3%) 161 (52.3%)
Unknown 8 (3.5%) 47 (15.3%)
Injury characteristics
Injury severity score (ISS) 0.006
Moderate (ISS 9–15) 153 (67.7%) 244 (79.2%)
Major (ISS 16–25) 67 (29.6%) 61 (19.8%)
Severe (ISS 26–74) 6 (2.7%) 3 (1.0%)
Unsurvivable (ISS = 75) 0 (0%) 0 (0.0%)
Mechanism of injury <0.001
Motor vehicle collision 56 (24.8%) 82 (26.6%)
Motorcycle collision 27 (11.9%) 50 (16.2%)
Pedestrian vs auto 7 (3.1%) 11 (3.6%)
Bicycle accident 25 (11.1%) 66 (21.4%)
Ground level fall 58 (25.7%) 37 (12.0%)
Fall from height 43 (19.0%) 42 (13.6%)
Other 10 (4.4%) 20 (6.5%)
Injuries
Number of rib fractures 6 (3–6) 5 (4–7) <0.001
Sternal fracture 18 (8.0%) 29 (9.4%) 0.67
Clavicular fracture 31 (13.7%) 46 (14.9%) 0.79
Scapular fracture 25 (11.1%) 41 (13.3%) 0.52
Pulmonary contusion 82 (36.3%) 121 (39.3%) 0.54
Hospitalization characteristics
Length of stay 5 (3–8) 3 (2–4) <0.001
Intensive care unit admission 172 (76.1%) 107 (34.7%) <0.001
Pneumonia 15 (6.6%) 1 (0.3%) <0.001
Discharge disposition <0.001
Home 125 (55.3%) 245 (79.5%)
Skilled nursing facility 57 (25.2%) 30 (9.7%)
Rehab 4 (1.8%) 4 (1.3%)
Acute care hospital 32 (14.2%) 23 (7.5%)
Other 8 (3.5%) 6 (1.9%)
30-day readmission 5 (2.2%) 4 (1.3%) 0.50
Mortality 7 (3.1%) 2 (0.6%) 0.04
IVL = intravenous lidocaine, IQR = interquartile range.
https://doi.org/10.1371/journal.pone.0239896.t001
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balance between the two groups by 48.1%. However, some imbalance remained with signifi-
cant differences between IVL and non-IVL groups on certain matching variables (Table 2).
Compared to the matched non-IVL group, IVL group patients were older (median age: 67.5 vs
59.5, p<0.001), had higher rates of serious injury (ISS > 15: 32.3% vs 19.5%, p = 0.006) and
more rib fractures (median: 6 vs 5, p = 0.006).
Fig 1. Increase in intravenous lidocaine use over the study period.
https://doi.org/10.1371/journal.pone.0239896.g001
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Main results
Unadjusted comparisons demonstrated no significant differences in daily opioid use between
IVL and non-IVL groups; however opioid use in the last 24 hours of admission was 40% lower
in the IVL group (p = 0.002, Table 3). There were no observed differences between IVL and
non-IVL groups in NRS pain score during admission hours 24–48. When stratified by age cat-
egory (�65 vs <65 years), there were no significant differences between IVL and non-IVL
groups in any primary outcome (Table 3).
Simple and multivariable linear regression results estimating the effect of IVL on daily opi-
oid use, opioid use in the last 24 hours of admission, and NRS pain score during admission
hours 24–48, adjusting for age category (�65 vs<65 years) as a moderating factor, and con-
trolling for HLOS and ISS are presented in Table 4. In univariate analyses, there was no signifi-
cant effect of IVL on the outcomes of interest. Similarly, in multivariable regression analyses,
there was no main effect of IVL on OME/day (p = 0.47), nor an interaction with age (p = 0.90).
Age was significantly associated with OME/day, with elderly patients receiving, on average,
64.2 fewer OME/day (95% CI [-87.53, -40.92], p<0.001). OME in the last 24 hours had similar
Table 2. Baseline characteristic comparison of propensity score-matched patients on vs not on IVL infusion.
IVL No IVL Median (IQR) or Number (%) n = 226
Median (IQR) or Number (%) n = 226 p
Age 67.5 (56.3–81.0) 59.5 (53.0–71.0) <0.001
Injury severity score (ISS) 0.006
Moderate (ISS 9–15 153 (67.7%) 182 (80.5%)
Major (ISS 16–25) 67 (29.6%) 42 (18.6%)
Severe (ISS 26–74) 6 (2.7%) 2 (0.9%)
Unsurvivable (ISS = 75) 0 (0%) 0 (0%)
Injuries
Number of rib fractures 6 (4–7) 5 (4–7) 0.006
Sternal fracture 18 (8.0%) 21 (9.3%) 0.74
Clavicular fracture 31 (13.7%) 33 (14.6%) 0.89
Scapular fracture 25 (11.1%) 32 (14.2%) 0.40
Pulmonary contusion 82 (36.3%) 80 (35.4%) 0.92
NRS pain score, admission hour 0–6 4.5 (2.4–6.0) 4.0 (2.5–6.2) 0.74
IVL = intravenous lidocaine, IQR = interquartile range, NRS = numeric rating scale.
https://doi.org/10.1371/journal.pone.0239896.t002
Table 3. Primary outcome comparison of patients on vs not on IVL infusion; all propensity score-matched patients and patients stratified by age subgroups.














n = 226 n = 226 n = 102 n = 148 n = 124 n = 78
OME per day, mg 65.5 (24.2–
120.6)
67.3 (32.6–116.6) 0.40 108.8 (70.6–
169.1)
97.6 (57.6–129.0) 0.09 33.2 (13.8–66.9) 29.8 (11.2–54.3) 0.33




75.0 (24.0–142.5) 0.002 97.5 (45.0–
135.0)
110.5 (52.5–159.0) 0.14 22.3 (3.8–52.6) 24.0 (0.0–60.0) 0.99
NRS pain score, admission
hours 24–48
3.3 (2.0–4.9) 3.4 (2.1–4.6) 0.70 4.3 (2.7–5.2) 3.8 (2.8–5.2) 0.69 2.5 (1.4–4.3) 2.2 (1.3–3.5) 0.28
Abbreviations: IVL = intravenous lidocaine, IQR = interquartile range, OME = oral morphine equivalents, NRS = numeric rating scale.
https://doi.org/10.1371/journal.pone.0239896.t003
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results, with no significant IVL effect (p = 0.53) or IVL by age interaction (p = 0.38) but a main
effect of age, with older participants receiving fewer OMEs in that time period (β = -78.31,
95% CI [-103.98, -52.95], p<0.001). Finally, average NRS pain scores did not significantly dif-
fer by IVL nor was the IVL by age interaction effect significant, but we observed a significant
main effect of age (β = -1.44, 95% CI [-1.92, -0.95], p<0.001), such that the older patients
reported lower pain scores.
Sensitivity analyses: Transformed OME outcomes
Similar to the primary analyses, we observed significant main effects of age on OME outcomes
in sensitivity analyses. There were no significant differences in OME/day by IVL group in uni-
variate or multivariable analyses. Unlike the primary analysis, the transformed OME in the last
24 hrs was significantly lower in IVL patients vs. non-IVL (p = 0.02) in univariate analysis.
However, the difference was no longer significant in multivariable analysis (p = 0.08) when
adjusted for covariates (age, age x IVL, HLOS and ISS).
Discussion
In propensity-matched analyses of adult rib fracture patients with isolated chest wall injury,
pain management with IVL was associated with a 40% lower opioid utilization in the last 24
hours of hospitalization in unadjusted comparisons. To the best of our knowledge, our study is
the first to evaluate an analgesic associated with reduced opioid use for rib fracture patients
during the last 24 hours of admission. The crude association between IVL and decreased opi-
oid use in the last 24 hours of admission is particularly interesting given this time period’s
association with opioid use at 90 days post-discharge, and possibly, post-discharge opioid pre-
scribing patterns. Clinicians may be more likely to prescribe post-discharge opioids based on
requirements during the last days, rather than early days, of admission.
However, the association between IVL and decreased opioid use in the last 24 hours of
admission was not seen when stratified by age group (<65 vs�65 years). In both adjusted and
unadjusted analyses, IVL was not significantly associated with opioid use during hospitaliza-
tion or pain scores during admission hours 24–48. Our findings show conflicting evidence
and only partially corroborate previous studies that showed an association between IVL use
and decreased opioid utilization after various operations [18–24]. Notably these studies
assessed opioid utilization at different time points after surgery, ranging from 6 hours to up to
72 hours [23, 24].
The retrospective nature of our study has inherent limitations. The decision to prescribe
IVL was based on clinician judgement. Although we performed propensity score matching
based on clinical factors that may influence whether a patient receives IVL, there remained
some differences between matched IVL and non-IVL groups that may be better controlled in a
randomized trial. The IVL group patients tended to be older, with more severe injuries, longer
hospitalizations, were more likely to be admitted to the SICU, and more likely to be discharged
Table 4. Linear regression results estimating IVL associations with OME and pain measures: Unadjusted estimates (univariate) and multivariable estimates
adjusted for injury severity score, hospital length of stay, and age (interaction).
OME per day, mg OME last 24 hours of admission, mg NRS pain score, admission hours 24–48
β [95% CI] p β [95% CI] p β [95% CI] p
IVL, unadjusted -0.68 [-17.4, 16.0] 0.94 -12.16 [-30.3, 6.0] 0.19 -0.08 [-0.43, 0.26] 0.63
IVL, adjusted 7.94 [-13.7, 29.6] 0.47 -7.55 [-31.4, 16.3] 0.53 -0.11 [-0.56, 0.35] 0.64
Abbreviations: IVL = intravenous lidocaine, OME = oral morphine equivalents, CI = confidence interval, NRS = numeric rating scale.
https://doi.org/10.1371/journal.pone.0239896.t004
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to a skilled nursing facility. This partially reflects our institutional practice, wherein any patient
65 or older with 2 or more rib fractures is initially monitored in the SICU. Additionally, IVL
may have been pre-emptively administered for patients expected to have worse pain or higher
opioid utilization, leading to a selection of older and sicker patients in the IVL group. We also
limited our study cohort to adults with isolated chest wall injuries and did not investigate the
impact of IVL for poly-trauma patients with rib fractures. Lastly, our clinical team ensures ade-
quate analgesia among rib fracture patients with deep inspiration and coughing, but we could
not delineate NRS pain scores recorded for specific activities. Studying NRS pain scores during
standardized activities (i.e. minimum incentive spirometry inspiration volume) may unveil
associations between IVL and pain scores among patients with rib fractures.
Future investigations evaluating the efficacy of IVL among patients with rib fractures will
need adequate statistical power to detect differences within stratified age groups (<65 and�65
years). Having shown opioid-sparing effect in other surgical populations, the efficacy of IVL
for other subgroups within the trauma population, such poly-trauma patients with rib frac-
tures, may be considered. Further investigations are also needed to uncover the underlying
mechanisms of IVL’s long-lasting analgesic effects.
Conclusion
Our findings suggest IVL requires further investigation for patients with traumatic rib frac-
tures; IVL was crudely associated decreased opioid requirements in the last 24 hours of admis-
sion, the time period associated with opioid use at 90 days post-discharge. However, given the
lack of observed IVL effects on opioids when stratified by age group and on multivariable
adjusted analyses, we are currently conducting a randomized controlled trial to further evalu-
ate the opioid-sparing effects of IVL. IVL is easy to deliver, easy to titrate, and has relatively
few contraindications; its analgesic effect is known to last long-term beyond the duration of
infusion. In addition to potentially minimizing opioid utilization during admission through
multimodality pain management, we must continue investigating analgesic strategies to
decrease opioid utilization after hospitalization.
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